# Vedolizumab

Source: https://onco.cc/drugs/vedolizumab/  
OnCo record `vedolizumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vedolizumab is a gut-targeted anti-inflammatory drip for ulcerative colitis and Crohn's disease, used when colitis caused by checkpoint immunotherapy does not settle with steroids and infliximab.

## Summary

The Entyvio label covers moderately to severely active ulcerative colitis and Crohn's disease in adults. SITC 2021: if colitis symptoms persist after the second infliximab dose, "the third dose should be held and 3 doses of vedolizumab (300 mg) should be administered at 0, 2, and 6 weeks" (LE 1); SITC notes that vedolizumab blocks alpha-4 beta-7 integrin, giving gut-selective anti-inflammatory activity. The use for immune-related colitis is off-label. The BLA was first approved on 20 May 2014.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-11-11
- Tags: supportive; generic; supportive-care-gaps-2026-11
- Brand: Entyvio
- Modality: Monoclonal antibody (gut-selective integrin receptor antagonist)
- Mechanism: A monoclonal antibody against alpha-4 beta-7 integrin that blocks immune cell traffic into the gut, giving a gut-selective anti-inflammatory effect.
- Approvals: US 2014: Moderately to severely active ulcerative colitis and Crohn's disease in adults

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Vedolizumab
- US label (DailyMed): Entyvio: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c
- Brahmer et al., SITC clinical practice guideline on immune checkpoint inhibitor-related adverse events (J Immunother Cancer 2021): https://doi.org/10.1136/jitc-2021-002435

## Connected records

- drugs: [Infliximab](https://onco.cc/drugs/infliximab/)
- terms: [Immune-mediated colitis and diarrhoea](https://onco.cc/terms/immune-colitis/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/)

---
JSON: https://onco.cc/api/v1/entities/vedolizumab.json